M. Pegram

747 total citations
14 papers, 571 citations indexed

About

M. Pegram is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, M. Pegram has authored 14 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Cancer Research and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in M. Pegram's work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). M. Pegram is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer, Hypoxia, and Metabolism (5 papers). M. Pegram collaborates with scholars based in United States, Poland and Luxembourg. M. Pegram's co-authors include DJ Slamon, D. Toppmeyer, Michael Smylie, Donald W. Northfelt, Agostino Riva, John Crown, David Reese, Ravi Patel, Mary-Ann Lindsay and Tadeusz Pieńkowski and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

M. Pegram

14 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Pegram United States	6	453	199	182	177	82	14	571
G. Box United Kingdom	10	337 0.7×	187 0.9×	115 0.6×	236 1.3×	69 0.8×	16	540
Roberta Guzman United States	8	539 1.2×	248 1.2×	289 1.6×	235 1.3×	107 1.3×	11	684
Daniela Kandioler-Eckersberger Austria	8	389 0.9×	235 1.2×	106 0.6×	220 1.2×	81 1.0×	11	583
Angela Santiago United States	7	516 1.1×	216 1.1×	289 1.6×	230 1.3×	115 1.4×	9	665
Martin Bezler Germany	4	279 0.6×	107 0.5×	95 0.5×	164 0.9×	81 1.0×	4	401
Sara Zaghlul United States	5	260 0.6×	144 0.7×	100 0.5×	300 1.7×	127 1.5×	8	492
Jeff Sperinde United States	15	495 1.1×	88 0.4×	337 1.9×	193 1.1×	124 1.5×	35	611
Yoomi Choi South Korea	7	379 0.8×	286 1.4×	172 0.9×	249 1.4×	127 1.5×	8	626
Yen-Chao Wang United States	3	322 0.7×	85 0.4×	140 0.8×	167 0.9×	69 0.8×	3	422
Marcia R. Campbell United States	9	343 0.8×	72 0.4×	210 1.2×	255 1.4×	103 1.3×	10	512

Countries citing papers authored by M. Pegram

Since Specialization

Citations

This map shows the geographic impact of M. Pegram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pegram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pegram more than expected).

Fields of papers citing papers by M. Pegram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Pegram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pegram. The network helps show where M. Pegram may publish in the future.

Co-authorship network of co-authors of M. Pegram

This figure shows the co-authorship network connecting the top 25 collaborators of M. Pegram. A scholar is included among the top collaborators of M. Pegram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Pegram. M. Pegram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Verma, Sunil, David Miles, Lorenzo Gianni, et al.. (2012). Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC). Annals of Oncology. 23. ixe5–ixe6. 2 indexed citations

Kittaneh, Muaiad, Alberto J. Montero, Víctor Amado, et al.. (2011). Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs).. Journal of Clinical Oncology. 29(15_suppl). 3081–3081. 1 indexed citations

Maltzman, J., M. Pegram, Saeed Sadeghi, et al.. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.. 1 indexed citations

Jameson, Michael B., Danny Rischin, M. Pegram, et al.. (2008). A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2562–2562. 1 indexed citations

Jameson, Michael B., Danny Rischin, M. Pegram, et al.. (2007). A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3516–3516. 3 indexed citations

Pegram, M., et al.. (2006). Current status and future directions of oral tyrosine kinase inhibitors in the treatment of cancer (part 3 of a 3-part series on angiogenesis inhibition in solid tumor malignancies).. 4. 1. 3 indexed citations

Patel, Kashyap, Yongchuan Gu, Kevin O. Hicks, et al.. (2006). 263 POSTER Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial. European Journal of Cancer Supplements. 4(12). 84–84. 1 indexed citations

Miller, Kathy D., HJ Burstein, Anthony Elias, et al.. (2005). Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 563–563. 57 indexed citations

Garland, Linda L., M. Pegram, Si Young Song, et al.. (2005). Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3152–3152. 8 indexed citations

10.

Ryan, Bríd M., Gottfried E. Konecny, Steffen Kahlert, et al.. (2005). Survivin protein expression predicts poor outcome in patients with primary breast cancer. Journal of Clinical Oncology. 23(16_suppl). 547–547. 1 indexed citations

11.

Konecny, G., Hans‐Joachim Lück, Michael Untch, et al.. (2004). HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer. JNCI Journal of the National Cancer Institute. 96(15). 1141–1151. 110 indexed citations

12.

Pegram, M., Tadeusz Pieńkowski, Donald W. Northfelt, et al.. (2004). Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer. JNCI Journal of the National Cancer Institute. 96(10). 759–769. 202 indexed citations

13.

Konecny, Gottfried E., Jane Arboleda, Carol Wilson, et al.. (2001). Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.. PubMed. 7(8). 2448–57. 58 indexed citations

14.

Pegram, M. & DJ Slamon. (2000). Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.. PubMed. 27(5 Suppl 9). 13–9. 123 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact